Immunitybio is trading 4.73% down at $8.36 on October 21, 2026, with no clear catalyst identified.
- The company completed the database lock for its 366-patient ANKTIVA-plus-BCG bladder cancer trial; topline results are expected in November.
- Available reporting did not link the announcement to the decline; one report said shares were higher when it was published.
- The biotech sector is up.